Aprea Therapeutics (APRE) Institutional Ownership $1.56 -0.02 (-1.26%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$1.60 +0.04 (+2.30%) As of 08/29/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Aprea Therapeutics (NASDAQ:APRE)CurrentInstitutional OwnershipPercentage34.19%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$251.48KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$297.77K Get APRE Insider Trade Alerts Want to know when executives and insiders are buying or selling Aprea Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data APRE Institutional Buying and Selling by Quarter Aprea Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 Exome Asset Management LLC28,972$59K0.1%-77.4%0.524% 5/14/2025 Stonepine Capital Management LLC102,242$209K0.2%-31.5%1.851% 2/17/2025 Stonepine Capital Management LLC149,221$491K0.4%+8.8%2.748% 2/17/2025 BNP Paribas Financial Markets13,011$43K0.0%N/A0.240% 2/12/2025 Landscape Capital Management L.L.C.35,328$116K0.0%N/A0.651% 2/11/2025 LPL Financial LLC16,052$53K0.0%N/A0.296% 8/21/2024 Stonepine Capital Management LLC137,174$558K0.5%N/A2.526% 8/9/2024 Dimensional Fund Advisors LP11,071$45K0.0%N/A0.204% 5/15/2023 AIGH Capital Management LLC345,000$1.53M0.6%N/A9.244% 5/15/2023 Sio Capital Management LLC280,000$1.24M0.6%N/A7.503% Get the Latest News and Ratings for APRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/12/2022Gyon Technologies Capital Management LP20,570$38K0.0%N/A0.094% 5/12/2022 Magnus Financial Group LLC14,856$28K0.0%-56.3%0.068% 2/15/2022 Kennedy Capital Management Inc.336,730$966K0.0%-1.7%1.569% 2/14/2022 PDT Partners LLC142,600$409K0.0%+62.5%0.664% 2/10/2022 Magnus Financial Group LLC33,981$98K0.0%N/A0.158% 11/16/2021 Verition Fund Management LLC20,101$103K0.0%N/A0.094% 11/12/2021 Geode Capital Management LLC198,339$1.01M0.0%+89.9%0.936% 11/10/2021 Goldman Sachs Group Inc.144,758$740K0.0%+131.4%0.683% 11/9/2021BlackRock Inc.354,275$1.81M0.0%-0.9%1.672% 9/17/2021 Virtu Financial LLC41,142$201K0.0%+292.9%0.194% 8/17/2021 Walleye Capital LLC98,931$483K0.0%-16.5%0.467% 8/17/2021 Walleye Trading LLC27,455$134K0.0%-33.4%0.130% 8/16/2021 PDT Partners LLC124,234$606K0.0%N/A0.586% 8/16/2021 Morgan Stanley1,019,776$4.98M0.0%+2.2%4.813% 8/16/2021 Kennedy Capital Management Inc.353,926$1.73M0.0%+575.2%1.670% 8/16/2021 Charles Schwab Investment Management Inc.50,366$246K0.0%-26.5%0.238% 8/16/2021 State Street Corp40,832$199K0.0%-67.2%0.193% 8/16/2021 Goldman Sachs Group Inc.62,546$305K0.0%-14.4%0.295% 8/13/2021 Northern Trust Corp32,530$159K0.0%-69.2%0.154% 8/13/2021 Geode Capital Management LLC104,447$509K0.0%-35.2%0.493% 8/13/2021 Vanguard Group Inc.707,422$3.45M0.0%-6.0%3.339% 8/12/2021 SG Americas Securities LLC598,395$2.92M0.0%-8.8%2.824% 8/12/2021 JPMorgan Chase & Co.60,315$294K0.0%+264.4%0.285% 8/12/2021Ergoteles LLC18,570$91K0.0%N/A0.088% 8/11/2021 Great Lakes Advisors LLC17,895$87K0.0%N/A0.084% 8/11/2021 Bank of New York Mellon Corp16,843$83K0.0%-64.8%0.079% 5/17/2021 Royal Bank of Canada15,173$76K0.0%+76.5%0.072% (Data available from 1/1/2016 forward) APRE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of APRE shares? During the previous two years, the following institutional investors and hedge funds held shares of Aprea Therapeutics shares: Stonepine Capital Management LLC ($209K), Landscape Capital Management L.L.C. ($116K), Exome Asset Management LLC ($59K), LPL Financial LLC ($53K), and Dimensional Fund Advisors LP ($45K), BNP Paribas Financial Markets ($43K).Learn more on Aprea Therapeutics' institutional investors. What percentage of Aprea Therapeutics' stock is owned by institutional investors? 34.19% of Aprea Therapeutics' stock is owned by institutional investors. Learn more on APRE's institutional investor holdings. Which institutional investors have been buying Aprea Therapeutics' stock? The following institutional investors have purchased Aprea Therapeutics' stock in the last 24 months: Stonepine Capital Management LLC ($149.22K), Landscape Capital Management L.L.C. ($35.33K), LPL Financial LLC ($16.05K), BNP Paribas Financial Markets ($13.01K), and Dimensional Fund Advisors LP ($11.07K). How much institutional buying is happening at Aprea Therapeutics? Institutional investors have bought a total of 76,438 shares in the last 24 months. This purchase volume represents approximately $251.48K in transactions. Which of Aprea Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Aprea Therapeutics stock in the last 24 months: Exome Asset Management LLC ($98.99K), and Stonepine Capital Management LLC ($46.98K). How much institutional selling is happening at Aprea Therapeutics? Institutional investors have sold a total of 145,967 shares in the last 24 months. This volume of shares sold represents approximately $297.77K in transactions. Related Companies OKUR Institutional Ownership XLO Institutional Ownership RVPH Institutional Ownership MURA Institutional Ownership SCYX Institutional Ownership ESLA Institutional Ownership HYPD Institutional Ownership RNXT Institutional Ownership THAR Institutional Ownership DYAI Institutional Ownership This page (NASDAQ:APRE) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
